

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5705353

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	PANGU BIOPHARMA LIMITED	01/30/2012
RECEIVING PARTY DATA		
Name:	ATYR PHARMA, INC.	
Street Address:	3545 JOHN HOPKINS COURT, SUITE 250	
City:	SAN DIEGO	
State/Country:	CALIFORNIA	
Postal Code:	92121	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16005045
CORRESPONDENCE DATA		
Fax Number:	(202)842-7899	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	(206) 452-8700	
Email:	lharveyjones@cooley.com	
Correspondent Name:	COOLEY LLP	
Address Line 1:	1299 PENNSYLVANIA AVE., N.W., SUITE 700	
Address Line 2:	ATTN: PATENT DEPARTMENT	
Address Line 4:	WASHINGTON, D.C. 20004	
ATTORNEY DOCKET NUMBER:	ATYR-015/06US 315789-2614	
NAME OF SUBMITTER:	MARK E. ROGEL	
SIGNATURE:	/Mark E. Rogel/	
DATE SIGNED:	09/06/2019	
Total Attachments: 2		
source=ATYR-015-06US_Pangu_to_aTyr#page1.tif		
source=ATYR-015-06US_Pangu_to_aTyr#page2.tif		

ASSIGNMENT

WHEREAS, Pangu BioPharma Limited (hereinafter referred to as "Pangu"), having a place of business at 18/F, Edinburgh Tower, The Landmark, 15 Queen's Road Central, Hong Kong, Special Administrative Region of the People's Republic of China, has rights in the following patent applications and the invention(s) disclosed therein:

Application No.	Title	Filing Date
U.S. 61/160,630	COMPOSITIONS AND METHODS COMPRISING HISTIDYL-IRNA SYNTHETASE SPLICE VARIANTS HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES	March 16, 2009
U.S. 61/239,747	COMPOSITIONS AND METHODS COMPRISING HISTIDYL-IRNA SYNTHETASE SPLICE VARIANTS HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES	September 3, 2009
U.S. 12/725,272	COMPOSITIONS AND METHODS COMPRISING HISTIDYL-IRNA SYNTHETASE SPLICE VARIANTS HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES	March 16, 2010
PCT/US2010/027525	COMPOSITIONS AND METHODS COMPRISING HISTIDYL-IRNA SYNTHETASE SPLICE VARIANTS HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES	March 16, 2010

WHEREAS, aTYR Pharma, Inc. (hereinafter referred to as "aTYR"), a corporation of the State of Delaware having a place of business at 3565 General Atomics Court, Suite 103, San Diego, California 92121, is desirous of acquiring a 50% undivided right, title and interest in and to Pangu's rights in said patent applications and invention(s) disclosed therein, and in and to any letters patent(s) that claim the priority benefit of said patent applications in the United States and in any and all foreign countries;

NOW, THEREFORE, for valuable consideration, the receipt of which is hereby acknowledged, Pangu hereby sells, assigns and transfers unto aTYR, a 50% undivided right, title and interest in and to Pangu's rights in said patent applications and invention(s) disclosed therein, and in and to any and all letters patent(s) which claim priority to said patent applications and any and all letters patent(s) which claim the invention(s) disclosed therein and which may be granted in the United States of America and its territorial possessions, including any extensions or adjustments in term thereof and in any and all foreign countries, and in any and all divisions, reissues and continuations thereof, including the right to file foreign applications directly in the name of aTYR and Pangu and to claim priority rights deriving from

said United States patent applications to which said foreign applications are entitled by virtue of international convention, treaty or otherwise, said invention(s), patent applications and all letters patent(s) on said invention(s) or claiming priority to said patent applications to be held and enjoyed by aTYR and its successors and assigns for their use and benefit. Pangu hereby authorizes and requests the Commissioner of Patents and Trademarks to issue jointly all letters patent on said invention(s) to aTYR and Pangu. Pangu agrees to execute all instruments and documents required for the making and prosecution of applications for United States and foreign letters patent on said invention(s), for litigation regarding said letters patent, or for the purpose of protecting title to said invention(s) or letters patent therefor.

1/30/2012
Date

John D. Mendlein
Name: John D. Mendlein
Title: Director, Pangu BioPharma Limited

I certify that I know or have satisfactory evidence that John D. Mendlein is the person who appeared before me, and said person acknowledged that he signed this instrument, on oath stated that he was authorized to execute the instrument, and acknowledged it as Director, Pangu BioPharma Limited, to be the free and voluntary act of said corporation(s) for the uses and purposes mentioned in the instrument.

Date 1/30/2012
(Type or Print)

Signed at 3565 Genem / Alamos Ct
San Diego, CA 92124

Bonnie Alexander
(Type or Print Name of Witness)

Bonnie Alexander
(Signature of Witness)